{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:11:25Z","timestamp":1793859085399,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["GA847762 (SMA-TB Project)"],"award-info":[{"award-number":["GA847762 (SMA-TB Project)"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drug-resistant tuberculosis remains a major global health challenge, and excessive inflammation may contribute to tissue damage and poor outcomes. We conducted a phase IIA prospective open-label pilot trial (ClinicalTrials.gov: NCT02781909) evaluating adjunctive ibuprofen in adults with pulmonary pre-extensively drug-resistant (pre-XDR) or extensively drug-resistant (XDR) tuberculosis in Georgia. Twenty-eight participants received individualized background anti-tuberculosis regimens alone (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914) or with ibuprofen 400\u2009mg daily for 2 months (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914) and were followed for 6 months. The primary efficacy outcome was the proportion of participants showing clinical and\/or microbiological benefit, assessed by sputum culture conversion, radiological evolution, and WHO-defined treatment outcomes. Secondary outcomes were safety and tolerability, health-related quality of life, and inflammatory and transcriptomic responses. Adding adjunctive ibuprofen did not improve month-2 sputum culture negativity, time to stable culture conversion, radiological evolution, or final treatment outcomes. Safety and tolerability were similar between groups. Adverse events were recorded and reviewed, but not formally graded for severity. Ibuprofen treatment was associated with numerically greater reductions in several blood-based inflammatory measures and in transcriptomic signature scores associated with poor tuberculosis outcomes. These findings are exploratory and do not demonstrate clinical benefit but indicate biological activity and support evaluation of anti-inflammatory host-directed therapies in larger controlled trials.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75148-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:13:55Z","timestamp":1782915235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a phase IIA open-label pilot clinical trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Kaori L.","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-0510","authenticated-orcid":false,"given":"Judith","family":"Farr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketevan","family":"Barbakadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iza","family":"Jikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malkhaz","family":"Tsotskhalashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3368-814X","authenticated-orcid":false,"given":"Juan M.","family":"Garc\u00eda-Illarramendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-8832","authenticated-orcid":false,"given":"Lilibeth","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Otwombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8778-3577","authenticated-orcid":false,"given":"Chiara","family":"Sopegno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Despuig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiia","family":"Buhiichyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamta","family":"Korinteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3044-1299","authenticated-orcid":false,"given":"\u00c9milie","family":"Layre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-2487","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Nigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestani","family":"Tukvadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergo","family":"Vashakidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-7270","authenticated-orcid":false,"given":"Cristina","family":"Vilaplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"75148_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2025 (WHO, 2025)."},{"key":"75148_CR2","unstructured":"World Health Organization. Tuberculosis Action Plan for the WHO European Region, 2023\u20132030 (WHO, 2023)."},{"key":"75148_CR3","doi-asserted-by":"crossref","unstructured":"Lange, C., Brehm, T. T., Chesov, D., Kherabi, Y. & Guglielmetti, L. Treatment of drug-susceptible and drug-resistant tuberculosis. in The Challenge of Tuberculosis in the 21st Century (E. R. S. Monograph) (eds Garc\u00eda-Basteiro, A. L., Ey\u00fcboglu, F. \u00d6. & Rangaka, M. X.) 117\u2013138 (European Respiratory Society, 2023).","DOI":"10.1183\/2312508X.10024622"},{"key":"75148_CR4","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","volume":"16","author":"A Zumla","year":"2016","unstructured":"Zumla, A. et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect. Dis. 16, e47\u2013e63 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"75148_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","volume":"23","author":"RS Wallis","year":"2023","unstructured":"Wallis, R. S., O\u2019Garra, A., Sher, A. & Wack, A. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat. Rev. Immunol. 23, 121\u2013133 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"75148_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fimmu.2017.00772","volume":"8","author":"VM Kroesen","year":"2017","unstructured":"Kroesen, V. M. et al. Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review. Front. Immunol. 8, 772 (2017).","journal-title":"Front. Immunol."},{"key":"75148_CR7","doi-asserted-by":"crossref","unstructured":"Young, C., Walzl, G. & Du Plessis, N. Therapeutic Host-Directed Strategies to Improve Outcome in Tuberculosis. Mucosal Immunol. 13, 190\u2013204 (2020).","DOI":"10.1038\/s41385-019-0226-5"},{"key":"75148_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","volume":"37","author":"G Varrassi","year":"2020","unstructured":"Varrassi, G., Pergolizzi, J. V., Dowling, P. & Paladini, A. Ibuprofen safety at the golden anniversary: Are all NSAIDs the sSame? A narrative review. Adv. Ther. 37, 61\u201382 (2020).","journal-title":"Adv. Ther."},{"key":"75148_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","volume":"208","author":"C Vilaplana","year":"2013","unstructured":"Vilaplana, C. et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199\u2013202 (2013).","journal-title":"J. Infect. Dis."},{"key":"75148_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/0883073811398132","volume":"26","author":"JF Schoeman","year":"2011","unstructured":"Schoeman, J. F., Janse Van Rensburg, A., Laubscher, J. A. & Springer, P. The role of aspirin in childhood tuberculous meningitis. J. Child Neurol. 26, 956\u2013962 (2011).","journal-title":"J. Child Neurol."},{"key":"75148_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2010.03.025","volume":"293","author":"UK Misra","year":"2010","unstructured":"Misra, U. K., Kalita, J. & Nair, P. P. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J. Neurol. Sci. 293, 12\u201317 (2010).","journal-title":"J. Neurol. Sci."},{"key":"75148_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/23744235.2020.1778177","volume":"52","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus. Infect. Dis. 52, 721\u2013729 (2020).","journal-title":"Infect. Dis."},{"key":"75148_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones, P. W., Quirk, F. H., Baveystock, C. M. & Littlejohns, P. A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire. Am. Rev. Respir. Dis. 145, 1321\u20131327 (1992).","journal-title":"Am. Rev. Respir. Dis."},{"key":"75148_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1017\/S0033291702006074","volume":"32","author":"RC Kessler","year":"2002","unstructured":"Kessler, R. C. et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol. Med. 32, 959\u2013976 (2002).","journal-title":"Psychol. Med."},{"key":"75148_CR15","unstructured":"World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update. https:\/\/www.who.int\/publications\/i\/item\/9789240063129 (2022)."},{"key":"75148_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-024-09009-5","volume":"24","author":"Y Wenlu","year":"2024","unstructured":"Wenlu, Y. et al. Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis. BMC Infect. Dis. 24, 1\u201313 (2024).","journal-title":"BMC Infect. Dis."},{"key":"75148_CR17","doi-asserted-by":"publisher","first-page":"101672","DOI":"10.1016\/j.smim.2022.101672","volume":"65","author":"D Tiwari","year":"2023","unstructured":"Tiwari, D. & Martineau, A. R. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. Semin. Immunol. 65, 101672 (2023).","journal-title":"Semin. Immunol."},{"key":"75148_CR18","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.2147\/IJGM.S483185","volume":"17","author":"X He","year":"2024","unstructured":"He, X., Hou, H., Jiang, Y. & Huang, X. Association between indices of peripheral blood inflammation and cavitary pulmonary tuberculosis. Int J. Gen. Med. 17, 5133\u20135142 (2024).","journal-title":"Int J. Gen. Med."},{"key":"75148_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247745","volume":"16","author":"TS Buttle","year":"2021","unstructured":"Buttle, T. S. et al. The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges. PLoS ONE 16, e0247745 (2021).","journal-title":"PLoS ONE"},{"key":"75148_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-020-01488-9","volume":"21","author":"FEA Hayford","year":"2020","unstructured":"Hayford, F. E. A. et al. The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis. Respir. Res. 21, 1\u201314 (2020).","journal-title":"Respir. Res."},{"key":"75148_CR21","doi-asserted-by":"publisher","first-page":"669623","DOI":"10.3389\/fcimb.2021.669623","volume":"11","author":"M J\u00f8ntvedt J\u00f8rgensen","year":"2021","unstructured":"J\u00f8ntvedt J\u00f8rgensen, M. et al. Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. Front. Cell. Infect. Microbiol. 11, 669623 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"75148_CR22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4049\/jimmunol.2200513","volume":"212","author":"WJ Pandori","year":"2024","unstructured":"Pandori, W. J. et al. Role for caspase-8 in the release of IL-1\u03b2 and active caspase-1 from viable human monocytes during toxoplasma gondii Infection. J. Immunol. 212, 1161\u20131171 (2024).","journal-title":"J. Immunol."},{"key":"75148_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tube.2017.08.004","volume":"107","author":"EG Thompson","year":"2017","unstructured":"Thompson, E. G. et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis 107, 48\u201358 (2017).","journal-title":"Tuberculosis"},{"key":"75148_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27029-6","volume":"12","author":"S Jenum","year":"2021","unstructured":"Jenum, S. et al. A Phase I\/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nat. Commun. 12, 6774 (2021).","journal-title":"Nat. Commun."},{"key":"75148_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07448-0","volume":"24","author":"L Arias","year":"2023","unstructured":"Arias, L. et al. SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen. Trials 24, 435 (2023).","journal-title":"Trials"},{"key":"75148_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious, S. A. Sample size of 12 per group rule of thumb for a pilot study. Pharm. Stat. 4, 287\u2013291 (2005).","journal-title":"Pharm. Stat."},{"key":"75148_CR27","doi-asserted-by":"crossref","unstructured":"Whitehead, A. L., Julious, S. A., Cooper, C. L. & Campbell, M. J. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat. Methods Med. Res. 25, 1057\u20131073 (2016).","DOI":"10.1177\/0962280215588241"},{"key":"75148_CR28","unstructured":"World Health Organization. Consolidated Guidance on Tuberculosis Data Generation and Use. Module 1. Tuberculosis Surveillance (WHO, 2024)."},{"key":"75148_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/00365540701558698","volume":"40","author":"C Wejse","year":"2008","unstructured":"Wejse, C. et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand. J. Infect. Dis. 40, 111\u2013120 (2008).","journal-title":"Scand. J. Infect. Dis."},{"key":"75148_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"75148_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05598-z","volume":"21","author":"WE Johnson","year":"2021","unstructured":"Johnson, W. E. et al. Comparing tuberculosis gene signatures in malnourished individuals using the TBSignatureProfiler. BMC Infect. Dis. 21, 1\u201313 (2021).","journal-title":"BMC Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75148-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:03:02Z","timestamp":1786532582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75148-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75148"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75148-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.G.I., C.S., and J.F. were employees of Anaxomics Biotech S.L., Barcelona, during part of the study. C.S. and J.F. are now at IGTP, Badalona, and J.M.G.I. is at VHIR, Barcelona. C.V. declares grant funding supporting this study (2021 SGR 00920, CPII18\/00031, PI20\/01424, CB06\/06\/0031, and SMA-TB project GA 847762), all paid to her institution. She is also a non-paid board member of 2 NPO: the foundation\n                      \n                      and ACTMON foundation (http:\/\/\n                      \n                      ), and the Secretary of TB & NTM group of the European Respiratory Society Assembly 10. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8185"}}